NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

You don't (or you shouldn't) call the continuation of a trial futile, unless the primary and secondary endpoints have both had a chance to be effectively measured. This assumes there are no safety concerns, which to our best knowledge, is the case here. There is valuable data to be collected and learning to be derived.

You don't continue to enroll patients in a trial that has a very low likelyhood of being able to provide an answer to the question the trial was originally designed to address. Those patients have the expectation that their involvement will help others (not help NWBO shareholders). The requirement for appropriately designed and conducted trials is mandated by the declaration of Helsinki which governs clinical research on human subjects.

I suspect that the adjudication process, which we know involves re-examining MRI's, indicates ....

This is a myth. The MRI's are examined by a blinded endpoint committee. Sadly, some here have morphed this into "re-examined".